Depsipeptide, a histone deacetylase inhibitor for treatment of cutaneous T-cell lymphoma

被引：0
|
作者：
不详
机构：
来源：
CLINICAL LYMPHOMA & MYELOMA | 2006年 / 6卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：358 / 364
页数：7
相关论文
共 50 条
  • [21] STAT3 Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor-Resistant Cutaneous T-Cell Lymphoma
    Takahashi, Yuto
    Kitadate, Akihiro
    Ikeda, Sho
    Iwama, Sayaka
    Abe, Ko
    Tagawa, Hiroyuki
    Wakui, Hideki
    Takahashi, Naoto
    BLOOD, 2022, 140 : 5971 - 5972
  • [22] Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma
    Fournier, Jean-Francois
    Bhurruth-Alcor, Yushma
    Musicki, Branislav
    Aubert, Jerome
    Aurelly, Michele
    Bouix-Peter, Claire
    Bouquet, Karinne
    Chantalat, Laurent
    Delorme, Marion
    Drean, Benedicte
    Duvert, Gwenaelle
    Fleury-Bregeot, Nicolas
    Gauthier, Blanche
    Grisendi, Karine
    Harris, Craig S.
    Hennequin, Laurent F.
    Isabet, Tatiana
    Joly, Florence
    Lafitte, Guillaume
    Millois, Corinne
    Morgentin, Remy
    Pascau, Jonathan
    Piwnica, David
    Rival, Yves
    Soulet, Catherine
    Thoreau, Etienne
    Tomas, Loic
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (17) : 2985 - 2992
  • [23] Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma
    Zhang, Huilai
    Dong, Ling
    Chen, Qingqing
    Kong, Lingzhe
    Meng, Bin
    Wang, Huaqing
    Fu, Kai
    Wang, Xi
    Pan-Hammarstrom, Qiang
    Wang, Ping
    Wang, Xianhuo
    LEUKEMIA RESEARCH, 2017, 56 : 29 - 35
  • [24] Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
    Piekarz, Richard L.
    Frye, Robin
    Turner, Maria
    Wright, John J.
    Allen, Steven L.
    Kirschbaum, Mark H.
    Zain, Jasmine
    Prince, H. Miles
    Leonard, John P.
    Geskin, Larisa J.
    Reeder, Craig
    Joske, David
    Figg, William D.
    Gardner, Erin R.
    Steinberg, Seth M.
    Jaffe, Elaine S.
    Stetler-Stevenson, Maryalice
    Lade, Stephen
    Fojo, A. Tito
    Bates, Susan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (32) : 5410 - 5417
  • [25] Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action
    Zhang, CL
    Richon, V
    Ni, X
    Talpur, R
    Duvic, M
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (05) : 1045 - 1052
  • [26] Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
    Ellis, Leigh
    Pan, Yan
    Smyth, Gordon K.
    George, Daniel J.
    McCormack, Chris
    Williams-Truax, Roxanne
    Mita, Monica
    Beck, Joachim
    Burris, Howard
    Ryan, Gail
    Atadja, Peter
    Butterfoss, Dale
    Dugan, Margaret
    Culver, Kenneth
    Johnstone, Ricky W.
    Prince, H. Miles
    CLINICAL CANCER RESEARCH, 2008, 14 (14) : 4500 - 4510
  • [27] Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas
    Khan, Omar
    La Thangue, Nicholas B.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (12): : 714 - 726
  • [28] Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas
    Omar Khan
    Nicholas B La Thangue
    Nature Clinical Practice Oncology, 2008, 5 : 714 - 726
  • [29] The Histone Deacetylase Inhibitor Vorinostat Induces Apoptosis in T-Cell Lymphoma Cell Lines and Synergizes with Bortezomib
    Cultrera, Jennifer L.
    Rosenberg, Lauren
    McConkey, David J.
    Pro, Barbara
    BLOOD, 2008, 112 (11) : 562 - 563
  • [30] Recalcitrant Subcutaneous Panniculitis-Like T-Cell Lymphoma Responsive to Histone Deacetylase Inhibitor
    Gleason, Laura
    Joffe, Daniel
    Bhatti, Safiyyah
    Cohen, Alexa
    Banner, Lauren
    Correia, Emily
    Alpdogan, Onder
    Porcu, Pierluigi
    Nikbakht, Neda
    CASE REPORTS IN ONCOLOGY, 2022, 15 (03): : 1088 - 1094
12345